UK Medicines Information
lenvatinib (Lenvima®) accepted for use within NHSScotland
Information type:
Guidance
Source:
Scottish Medicines Consortium
Specialities:
Cancers | Liver disorders
Summary
The SMC has accepted lenvatinib as monotherapy for treatment of adults with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy. The advice takes account benefits of a Patient Access Scheme that improves cost effectiveness of lenvatinib.
UKMi comment
NICE (TA551) has also previously recommended lenvatinib as an option for untreated, advanced, unresectable hepatocellular carcinoma in adults, only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and, the company provides it according to the commercial arrangement.
Related links:
NICE TA551 (December 2018)